Francis S H
Department of Molecular Physiology and Biophysics, Vanderbilt University School of Medicine, Nashville, TN 37232-0615, USA.
Int J Impot Res. 2005 Sep-Oct;17(5):467-8. doi: 10.1038/sj.ijir.3901377.
PDE11, the newest member of the PDE family of phosphodiesterases, has become the center of controversy. Four splice variants were recently identified, PDE11A1-4. Historical data have suggested that PDE11A3 is found in the testis while PDE11A4 is found in the prostate. The controversial issue is the inhibition of PDE11 by tadalafil. In the light of tadalafil's commercial success, its inhibition of PDE11A has been the subject of heated debate. A variety of published reports addressed this issue, suggesting that the target organ of tadalafil's inhibition, the testis, is not adversely affected. Daily tadalafil given to healthy volunteers did not alter semen analysis parameters or blood hormonal parameters, seemingly mitigating the clinical effect of the PDE11 inhibition. However, two recent papers published in this journal have added fuel to this proverbial fire. In this perspective, Sharron Francis, a noted PDE expert, and a co-author of one of the recent papers mentioned above, sheds further light on this contested topic.
磷酸二酯酶(PDE)家族的最新成员PDE11已成为争议的焦点。最近发现了四种剪接变体,即PDE11A1 - 4。历史数据表明,PDE11A3存在于睾丸中,而PDE11A4存在于前列腺中。有争议的问题是他达拉非对PDE11的抑制作用。鉴于他达拉非在商业上的成功,其对PDE11A的抑制作用一直是激烈辩论的主题。各种已发表的报告都涉及了这个问题,表明他达拉非抑制作用的靶器官——睾丸——并未受到不利影响。给予健康志愿者每日服用他达拉非并未改变精液分析参数或血液激素参数,这似乎减轻了PDE11抑制的临床效果。然而,该杂志最近发表的两篇论文给这一众所周知的争议火上浇油。在这篇观点文章中,著名的PDE专家、上述近期论文之一的共同作者莎伦·弗朗西斯进一步阐明了这个有争议的话题。